Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | FPR2 | P25090 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 5/20 | 0.57 |
| ▸ | CIT | O14578 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452307 | 1.00 | KMT2A (0.65) | KMT2AL3MBTL1FPR2ALDH1A1MAPT | |
| SCHEMBL7039856 | 0.94 | HDAC8 (0.66) | KMT2AL3MBTL1FPR2ALDH1A1RAB9A | |
| SCHEMBL28974545 | 0.88 | GAA (0.63) | KMT2AALDH1A1MAPTHDAC8LTA4H | |
| SCHEMBL28279155 | 0.88 | MAPT (0.66) | KMT2AL3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL28279153 | 0.88 | MAPT (0.66) | KMT2AL3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL11120483 | 0.87 | RAB9A (0.59) | KMT2AL3MBTL1FPR2ALDH1A1MAPT | |
| SCHEMBL2994486 | 0.87 | BACE1 (0.57) | KMT2ARAB9ASMN1; SMN2HDAC8LTA4H | |
| SCHEMBL2994483 | 0.87 | BACE1 (0.57) | KMT2ARAB9ASMN1; SMN2HDAC8LTA4H | |
| SCHEMBL21880164 | 0.85 | RAB9A (0.67) | KMT2AALDH1A1MAPTRAB9AROCK2 | |
| SCHEMBL21880165 | 0.85 | RAB9A (0.67) | KMT2AALDH1A1MAPTRAB9AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| JP-2004182670-A | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-PROTECTED INDOLINE-2-CARBOXYLIC ACID DERIVATIVE AND METHOD FOR PRODUCING OPTICALLY ACTIVE INDOLINE-2-CARBOXYLIC ACID DERIVATIVE | TORAY IND INC | 2004-07-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | KMT2A 3986/4885L3MBTL1 2230/4885FPR2 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.